Nexavar included in NICE's thyroid cancer recommendations

Nexavar (sorafenib) is by no means Bayer’s (BAYN: DE) newest cancer drug but there is life in the blockbuster yet – as shown by a new recommendation from the National Institute for Health and Care Excellence (NICE).

Previously this drug was only available in England on the Cancer Drugs Fund for progressive, locally advanced or metastatic differentiated thyroid cancer in adults whose disease does not respond to radioactive iodine (RAI), despite the fact that it was approved by the European Medicines Agency in this indication in May 2014.

Now the NICE has made the drug available for routine funding on the National Health Service.